利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.021 秒)

    Compositions and Methods for Oral Delivery of Therapeutic Cargo
    2.
    发明申请
    Compositions and Methods for Oral Delivery of Therapeutic Cargo 审中-公开

    公开(公告)号：US20190388520A1

    公开(公告)日：2019-12-26

    申请号：US16414686

    申请日：2019-05-16

    申请人： Applied Molecular Transport Inc.

    发明人： Randall J. Mrsny ,  Tahir Mahmood

    IPC分类号： A61K38/45 ,  A61K38/20 ,  C07K16/24 ,  C12N9/10 ,  A61K38/17 ,  A61K38/26 ,  A61K38/27

    摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.

    COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATION
    5.
    发明申请
    COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATION 有权

    公开(公告)号：US20220112259A1

    公开(公告)日：2022-04-14

    申请号：US17512315

    申请日：2021-10-27

    申请人： Applied Molecular Transport Inc.

    发明人： Derek Maclean ,  Randall J. Mrsny ,  Kevin Yin

    IPC分类号： C07K14/54 ,  C07K1/14 ,  C07K1/18 ,  C07K1/34 ,  C07K1/36 ,  C07K14/28 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

    摘要： Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.